研究所

トップページ研究所研究分野紹介がん病態生理学分野業績

がん病態生理学分野 業績

原著論文

  1. Li Y, Fujishita T, Mishiro-Sato E, Kojima Y, Niu Y, Taketo M, Urano Y, Sakai T, Enomoto A, Nishida Y, Aoki M.: TGF-β signaling promotes desmoid tumor formation via CSRP2 upregulation. Cancer Sci, 115(2): 401-411, 2023. doi: 10.1111/cas.16037. 
  2. Kojima Y, Mishiro-Sato E, Fujishita T, Satoh K, Kajino-Sakamoto R, Oze I, Nozawa K, Narita Y, Ogata T, Matsuo K, Muro K, Taketo MM, Aoki M.: Decreased liver B vitamin-related enzymes as a metabolic hallmark of cancer cachexia. Nat Commun, 14(1):6246, 2023. doi: 10.1038/s41467-023-41952-w.
  3. Tabata S, Kojima Y, Sakamoto T, Igarashi K, Umetsu K, Ishikawa T, Hirayama A, Kajino-Sakamoto R, Sakamoto N, Yasumoto K, Okano K, Suzuki Y, Yachida S, Aoki M, Soga T.: L-2hydroxyglutaric acid rewires amino acid metabolism in colorectal cancer via the mTOR-ATF4 axis. Oncogene, 42 (16): 1294-1307, 2023. doi: 10.1038/s41388-023-02632-7.
  4. Amada K, Hijiya N, Ikarimoto S, Yanagihara K, Hanada T, Hidano S, Kurogi S, Tsukamoto Y, Nakada C, Kinoshita K, Hirashita Y, Uchida T, Shin T, Yada K, Hirashita T, Kobayashi T, Murakami K, Inomata M, Shirao K, Aoki M, Takekawa M, Moriyama M.: Involvement of clusterin expression in the refractory response of pancreatic cancer cells to a MEK inhibitor. Cancer Sci. 114 (5): 2189-2202, 2023. doi: 10.1111/cas.15735. 
  5. Fujishita T, Kojima Y, Kajino-Sakamoto R, Mishiro-Sato E, Shimizu Y, Hosoda W, Yamaguchi R, Taketo MM, Aoki M.: The cAMP/PKA/CREB and TGF-β/SMAD4 pathways regulate stemness and metastatic potential in colorectal cancer cells. Cancer Res. 82(22): 4179-4190, 2022, doi: 10.1158/0008-5472.CAN-22-1369. Online ahead of print. (PMID: 36066360)
  6. Sakuma K, Sasaki E, Hosoda Y, Komori K, Shimizu Y, Yatabe Y, Aoki M.: MYB mediates downregulation of the colorectal cancer metastasis suppressor HNRNPLL during epithelial-mesenchymal transition. Cancer Sci. 112(9): 3846-3855, 2021. doi: 10.1111/cas.15069. (PMID: 34286904)
  7. Tanigawa S, Fujita M, Mayama C, Ando S, Ii H, Kojima Y, Fujishita T, Aoki M, Takauchi H, Yamanaka T, Takahashi Y, Hashimoto N, Nakata S.: Inhibition of Gli2 suppresses tumorigenicity in glioblastoma stem cells derived from a de novo murine brain cancer model. Cancer Gene Ther, a28 (12): 1339-1352, 2021, doi: 10.1038/s41417-020-00282-5. (PMID: 33414520)
  8. Kajino-Sakamoto R, Fujishita T, Taketo MM, Aoki M.: Synthetic lethality between MyD88 loss and mutations in Wnt/β-catenin pathway in intestinal tumor epithelial cells. Oncogene. 40(2): 408-420, 2021. doi: 10.1038/s41388-020-01541-3. (PMID: 33177648)
  9. Kojima Y, Kondo Y, Fujishita T, Mishiro-Sato E, Kajino-Sakamoto R, Taketo MM, Aoki M. Stromal iodothyronine deiodinase 2 (DIO2) promotes the growth of intestinal tumors in ApcΔ716 mutant mice. Cancer Sci. 110(8):2520-2528, 2019. doi: 10.1111/cas.14100. (PMID: 31215118)
  10. Hijioka S, Sakuma K, Aoki M, Mizuno N, Kuwahara T, Okuno N, Hara K, Yatabe Y.: Clinical and in vitro studies of the correlation between MGMT and the effect of streptozocin in pancreatic NET. Cancer Chemother Pharmacol, 83(1):43-52, 2019. doi: 10.1007/s00280-018-3700-y. (PMID: 30310970)
  11. Matsushita A, Sato T, Mukai S, Fujishita T, Mishiro E, Aoki M, Hasegawa Y, Sekodo Y. TAZ activation by Hippo pathway dysregulation induces cytokine gene expression and promotes mesothelial cell transformation. Oncogene, 38(11):1966-1978, 2019. doi: 10.1038/s41388-018-0417-7. (PMID: 30401981)
  12. Maeda A, Irie K, Ando H, Hasegawa A, Taniguchi H, Kadowaki S, Muro K, Tajika M, Aoki M, Inaguma K, Kajita M, Fujimura A, Fukushima S.: Associations among regorafenib concentrations, severe adverse reactions, and ABCG2 and OATP1B1 polymorphisms. Cancer Chemother Pharmacol, 83(1):107-113, 2019. doi: 10.1007/s00280-018-3710-9. (PMID: 30368586)
  13. Sakuma K, Sasaki E, Kimura K, Komori K, Shimizu Y, Yatabe Y, Aoki M. HNRNPLL stabilizes mRNAs for DNA replication proteins and promotes cell cycle progression in colorectal cancer cells. Cancer Sci. 109(8):2458-2468, 2018. doi: 10.1111/cas.13660. (PMID: 29869816)
  14. Satoh K, Yachida S, Sugimoto M, Oshima M, Nakagawa T, Akamoto S, Tabata S, Saitoh K, Kato K, Sato S, Igarashi K, Aizawa Y, Kajino-Sakamoto R, Kojima Y, Fujishita T, Enomoto A, Hirayama A, Ishikawa T, Taketo MM, Kushida Y, Haba R, Okano K, Tomita M, Suzuki Y, Fukuda S, Aoki M, Soga T. Global metabolic reprogramming of colorectal cancer occurs at adenoma stage and is induced by MYC. PNAS, 114(31): 8289-8294, 2017. doi: 10.1073/pnas.1620915114. (PMID: 28716939)
  15. Sakuma K, Sasaki E, Kimura K, Komori K, Shimizu Y, Yatabe Y, Aoki M.: HNRNPLL, a newly identified colorectal cancer metastasis suppressor, modulates alternative splicing of CD44 during epithelial-mesenchymal transition. Gut. 67(6): 1103-1111, 2018. doi: 10.1136/gutjnl-2016-312927. (PMID: 28360095)
  16. Cao X, Kajino-Sakamoto R, Doss A, Aballay A. Distinct Roles of Sensory Neurons in Mediating Pathogen Avoidance and Neuropeptide-Dependent Immune Regulation. Cell Rep. 2017 Nov 7;21(6):1442-1451. doi: 10.1016/j.celrep.2017.10.050.
  17. Maeda A, Ando H, Ura T, Muro K, Aoki M, Saito K, Kondo E, Takahashi S, Ito Y, Mizuno Y, Fujimura A. Differences in urinary renal failure biomarkers in cancer patients initially treated with cisplatin. Anticancer Res. 37(9): 5235-5339, 2017. doi: 10.21873/anticanres.11947. (PMID: 28870959)
  18. Fujishita T, Kojima Y, Kajino-Sakamoto, R, Taketo, MM, Aoki M. Tumor microenvironment confers mTOR inhibitor resistance in invasive intestinal adenocarcinoma. Oncogene. 36(46): 6480-6489, 2017. doi: 10.1038/onc.2017.242. (PMID: 28759045)
  19. Maeda A, Ando H, Ura T, Komori A, Hasegawa A, Taniguchi H, Kadowaki S, Muro K, Tajika M, Kobara M, Matsuzaki M, Hashimoto N, Maeda M, Kojima Y, Aoki M, Kondo E, Mizutani A, Fujimura A. Association between and polymorphisms and adverse drug reactions to regorafenib: A preliminary study. Int J Clin Pharmacol Ther. 55(5): 409-415, 2017. doi: 10.5414/CP202788. (PMID: 28157071)
  20. Hashimoto K, Simmons AN, Kajino-Sakamoto R, Tsuji Y, Ninomiya-Tsuji J. TAK1 regulates the Nrf2 antioxidant system through modulating p62/ SQSTM1. Antioxid Redox Signal. 25: 953-964, 2016 (PMID: 27245349)
  21. Hijiya N, Tsukamoto Y, Nakada C, Tung N, Kai T, Matsuura K, Shibata K, Inomata M, Uchida T, Tokunaga A, Amada K, Shirao K, Yamada Y, Mori H, Takeuchi I, Seto M, Aoki M, Takekawa M, Moriyama M.: Genomic loss of DUSP4 contributes to the progression of intraepithelial neoplasm of pancreas to invasive carcinoma. Cancer Res. 76:2612-2625, 2016 (PMID: 26941286)
  22. Simmons AN, Kajino-Sakamoto R, Ninomiya-Tsuji J.: TAK1 regulates Paneth cell integrity partly through blocking necroptosis. Cell Death Dis. 7:e2196, 2016 (PMID: 27077812)
  23. Fujishita T, Kajino-Sakamoto R, Kojima Y, Taketo MM, Aoki M.: Antitumor activity of the MEK inhibitor trametinib on intestinal polyp formation in ApcΔ716 mice involves stromal COX-2. Cancer Sci, 106: 692-699, 2015 (PMID:25855137)
  24. Hirai H, Fujishita T, Kurimoto K, Miyachi H, Kitano S, Inamoto S, Itatani Y, Saitou M, Maekawa T,Taketo MM.: CCR1-mediated accumulation of myeloid cells in the liver microenvironment promoting mouse colon cancer metastasis. Clin Exp Metastasis, 31: 977-989, 2014 (PMID: 25326065)
  25. Patnode M, Yu S-Y, Cheng C-W, Ho M-Y, Tegesjo L, Sakuma K, Uchimura K, Khoo K-H, Kannagi R, Rosen S.: KSGal6ST generates galactose-6-O-sulfate in high endothelial venules but does not contribute to L-selectin dependent lymphocyte homing. Glycobiology, 23: 381-394, 2013. (PMID: 23254996)
  26. Itatani Y, Kawada K, Fujishita T, Kakizaki F, Hirai H, Matsumoto T, Iwamoto M, Inamoto S, Hatano E, Hasegawa S, Maekawa T, Uemoto S, Sakai Y, Taketo MM.: Loss of SMAD4 from colorectal cancer cells promotes CCL15 expression to recruit CCR1+ myeloid cells and facilitate liver metastasis. Gastroenterology, 145: 1064-1075, 2013. (PMID: 23891973)
  27. Sakuma K, Furuhashi T, Kondo S, Yabe U, Ohmori K, Ito H, Aoki M, Morita A, Kannagi R.: Sialic acid cyclization of human Th homing receptor glycan associated with recurrent exacerbations of atopic dermatitis. J Dermatol Sci, 68: 187-193, 2012. (PMID: 23088960)
  28. Sakuma K, Aoki M, Kannagi R.: Transcription factors c-MYC and CDX2 mediate E-selectin ligand expression in colon cancer cells undergoing EGF/bFGF-induced epithelial-mesenchymal transition. Proc Natl Acad Sci U S A, 109: 7776-7781, 2012. (PMID: 22547830)
  29. Miyazaki K, Sakuma K, Kawamura Y, Izawa M, Ohmori K, Mitsuki M, Yamaji T, Hashimoto Y, Suzuki A, Saito Y, Dohi T, Kannagi R.: Colonic epithelial cells express specific ligands for mucosal macrophage immunosuppressive receptors siglec-7 and -9. J Immunol, 188: 4690-700, 2012. (PMID: 22467657)
  30. Sakuma K, Chen GY, Aoki M, Kannagi R.: Induction of 6-sulfated glycans with cell adhesion activity via T-bet and GATA-3 in human helper T cells. Biochim Biophys Acta, 1820: 841-848, 2012. (PMID: 22446378)
  31. Fujishita T, Aoki M, Taketo MM.: JNK signaling promotes intestinal tumorigenesis through activation of mTOR complex 1 in ApcΔ716 mice. Gastroenterology, 140:1556-1563, 2011. (PMID: 21320501)
  32. Aoki K, Kakizaki F, Sakashita H, Manabe T, Aoki M, Taketo MM.: Suppression of colonic polyposis by homeoprotein CDX2 through its nontranscriptional function that stabilizes p27Kip1. Cancer Res, 71: 593-602, 2011. (PMID: 21224344)
  33. Sonoshita M, Aoki M, Fuwa H, Aoki K, Hosogi H, Sakai Y, Hashida H, Takabayashi A, Sasaki M, Robine S, Itoh K, Yoshioka K, Kakizaki F, Kitamura T, Oshima M, Taketo MM.: Suppression of colon cancer metastasis by Aes through inhibition of Notch signaling. Cancer Cell, 19: 125-137, 2011. (PMID: 21251616)
  34. Sun J, Singh V, Kajino-Sakamoto R, Aballay A. Neuronal GPCR controls innate immunity by regulating noncanonical unfolded protein response genes. Science, 332: 729-732, 2011. (PMID: 21474712)
  35. Kitamura T, Fujishita T, Loetscher P, Revesz L, Hashida H, Kizaka-Kndoh S, Aoki M, Taketo MM.: Inactivation of chemokine (C-C motif) receptor 1 (CCR1) suppresses colon cancer liver metastasis by blocking accumulation of immature myeloid cells in a mouse model. Proc Natl Acad Sci USA, 107: 13063-13068, 2010. (PMID: 20616008)
  36. Deguchi A, Miyoshi H, Kojima Y, Okawa K, Aoki M, Taketo MM.: LKB1 suppresses p21-activated kinase-1 (PAK1) by phosphorylation of Thr109 in the p21-binding domain. J Biol Chem, 285: 18282-18290, 2010. (PMID: 20400510)
  37. Kakizaki F, Aoki K, Miyoshi H, Carrasco N, Aoki M, Taketo MM.: CDX transcription factors positively regulate expression of Solute Carrier Family 5, Member 8 in the colonic epithelium. Gastroenterology, 138: 627-635, 2010. (PMID: 19900445)
  38. Kajino-Sakamoto R, Omori E, Nighot PK, Blikslager AT, Matsumoto K, Ninomiya-Tsuji J. TGF-beta-activated kinase 1 signaling maintains intestinal integrity by preventing accumulation of reactive oxygen species in the intestinal epithelium. J Immunol, 185: 4729-4727, 2010. (PMID: 20855879)
  39. Kojima Y, Acar A, Eaton EN, Mellody KT, Scheel C, Ben-Porath I, Onder TT, Wang ZC, Richardson AL, Weinberg RA, Orimo A. Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proc Natl Acad Sci U S A, 107: 20009-20014, 2010. (PMID: 21041659)
  40. Kitamura T, Biyajima K, Aoki M, Oshima M and Taketo MM. Matrix metalloproteinase 7 is required for tumor formation, but dispensable for invasion and fibrosis in SMAD4-deficient intestinal adenocarcinomas. Lab. Invest, 89: 98-105, 2009. (PMID: 19002110)
  41. Arimura S, Matsunaga A, Kitamura T, Aoki K, Aoki M, Taketo MM. Reduced level of Smoothened suppresses intestinal tumorigenesis by down-regulation of Wnt signaling. Gastroenterology, 137: 629-638, 2009. (PMID: 19427313)
  42. Miyoshi H, Deguchi A, Nakau M, Kojima Y, Mori A, Oshima M, Aoki M, Taketo MM. Hepatocellular carcinoma development induced by conditional beta-catenin activation in Lkb1 mice. Cancer Sci, 100: 2046-2053, 2009. (PMID: 19671058)
  43. Morioka S, Omori E, Kajino T, Kajino-Sakamoto R, Matsumoto K, Ninomiya-Tsuji J. TAK1 kinase determines TRAIL sensitivity by modulating reactive oxygen species and cIAP. Oncogene, 28: 2257-2265, 2009. (PMID: 19421137)
  44. Kim JY, Kajino-Sakamoto R, Omori E, Jobin C, Ninomiya-Tsuji J. Intestinal epithelial-derived TAK1 signaling is essential for cytoprotection against chemical-induced colitis. PLoS One, 4: e4561, 2009. (PMID: 19234607)

総説、著書等

  1. Aoki, M. and Fujishita, T. Oncogenic Roles of the PI3K/AKT/mTOR Axis. Curr Top Microbiol Immunol.  407: 153-189, 2017. (PMID: 28550454)
  2. Aoki M, Taketo MM. Use of Genetically Engineered Mouse Models in Identification and Validation of Therapeutic Targets for Colon Cancer. in Targeting the Wnt Pathway in Cancer ed. Goss, Kahn. 2011. Springer, New York. (ISBN: 978-1-4419-8022-9)
  3. Fujishita T, Aoki M, Taketo MM. The role of mTORC1 pathway in intestinal tumorigenesis. Cell Cycle, 22: 3684-3687, 2009. (PMID: 19855161)
  4. Kannagi R, Sakuma K, Miyazaki K, Lim KT, Yusa A, Yin J, Izawa M. Altered expression of glycan genes in cancers induced by epigenetic silencing and tumor hypoxia: Clues in the ongoing search for new tumor markers. Cancer Sci, 101: 586-593, 2009. (PMID: 20085584)